Tag: Second-generation H1 antihistamine (peripheral)

  • Loratadine

    Second-generation H1 antihistamine (peripheral)

    A piperidine second-generation H1 antihistamine; a non-sedating allergy medication and the prodrug of desloratadine.

    Abstract

    Loratadine (ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate; CAS 79794-75-5; molecular formula C22H23ClN2O2; molecular weight 382.88) is a piperidine second-generation H1 antihistamine developed at Schering-Plough and approved by the FDA in 1993 (Claritin). H1 affinity is approximately 100 nM, lower than cetirizine but with similar peripheral selectivity (minimal CNS penetration). The principal active species is the metabolite desloratadine (formed via CYP3A4 and CYP2D6), which has higher H1 affinity (approximately 0.4 nM) and longer half-life; desloratadine is marketed separately as Clarinex. Plasma half-life of loratadine is approximately 8 hours; desloratadine half-life is approximately 27 hours. Approved indications: allergic rhinitis, urticaria. Sedation incidence is approximately 8 percent (similar to placebo in most trials), the lowest of the second-generation antihistamines. Used as the canonical non-sedating H1 antihistamine in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cetirizine

    Second-generation H1 antihistamine (peripheral)

    A second-generation peripheral H1 antihistamine; the principal active metabolite of hydroxyzine without CNS penetration.

    Abstract

    Cetirizine (2-[2-[4-[(R/S)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl]ethoxy]acetic acid; CAS 83881-51-0; molecular formula C21H25ClN2O3; molecular weight 388.89) is a second-generation H1 antihistamine developed at UCB and approved by the FDA in 1995 (Zyrtec). The compound is the principal active carboxylic acid metabolite of hydroxyzine; the addition of the carboxyl group eliminates blood-brain barrier penetration, producing peripheral H1 antagonism without the central sedating effects of hydroxyzine. H1 selectivity is high; minimal anticholinergic activity. Plasma half-life is approximately 8 hours; minimal hepatic metabolism (excreted largely unchanged renally). The compound has minor sedating effect in approximately 10 to 15 percent of users (slightly more than fexofenadine or loratadine), reflecting some BBB penetration. Approved indications: allergic rhinitis, urticaria, allergic conjunctivitis. Used as the canonical second-generation peripheral H1 antagonist in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.